AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02242799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50mg od
Description: Dolutegravir 50mg once daily will be given either alone or in combination, as specified
Study NCT02242799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine combination
Description: Artemether-lumefantrine combination will be given both alone and in combination with Dolutegravir 50mg od in order to assess changes in PK
Study NCT02242799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine
Description: Artesunate-amodiaquine will be given alone or in combination with Dolutegravir 50mg od (in a parallel study design) in order to assess the potential interaction causing changes in PK parameters
Study NCT01002911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin, Bacitracin, Cefalexin
Description: Single does of Cefazolin 1-2 g iv given over 60-120 minutes, 60-120 minutes prior to skin incision, Bacitracin wash, Cefalexin 250-500 mg TID
Study NCT01002911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Description: Cefazolin 1-2 g iv given over 60-120 minutes, 60-120 minutes prior to skin incision
Study NCT02380638 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole-body vibration training (Power Plate®) on bone mass and bone metabolism in adolescents with and without Down syndrome.
Study NCT01315197 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: Massage Anmá: 7-8 sessions, twice per week, kneading and pressure points on the bladder meridian
Study NCT03503162 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pure-Vu System
Description: The Pure-Vu System is FDA cleared device and CE marking received in February 2018, intended to connect to standard colonoscopes to help facilitate intra-procedural cleaning of a poorly prepared colon by irrigating or cleaning the colon and evacuating the irrigation fluid (water), feces and other bodily fluids and matter, e.g. blood.
Study NCT02513979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Angiotensin type II receptor antagonists
Description: Angiotensin type II receptor antagonists given to hypertensive patients treated with high blood pressure
Study NCT02668796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol Vaginal Tablets 10 mcg (Glenmark)
Description: apply using the given applicator
Study NCT02668796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vagifem® (Estradiol Vaginal Tablets) 10 mcg (Novo Nordisk)
Description: apply using the given applicator
Study NCT02668796 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Estradiol Vaginal Tablets 10 mcg (Glenmark)
Description: apply using the given applicator
Study NCT03692221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MSC Treatment group 2 (high dose)
Description: Autologous Bone Marrow Derived Mesenchymal Stem Cells (MSC) - A one time injection of 1-2 ml of a 4 x 106/ml concentration solution
Study NCT03692221 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Control (no treatment)
Description: Comparative analysis of psychometric and morphometric based data
Study NCT02250183 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MEDIHONEY® GEL WITH ACTIVE LEPTOSPERMUM HONEY
Description: MEDIHONEY® GEL WITH ACTIVE LEPTOSPERMUM HONEY dressing is manufactured by the company Derma Sciences, Inc. and is a moist dressing made of Active Leptospermum Honey (+15) in combination with natural gelling agents. The gelling agents act to maintain the physical integrity and viscosity of the dressing, even in the presence of body heat and fluids. As a percentage of the overall dressing, MEDIHONEY® GEL dressings contains 80% honey. The dressing has a low pH and can help to lower the overall pH of wounds. The dressing also possesses a high osmotic potential, which assists in debridement.
Study NCT02250183 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Santyl
Description: SANTYL® Ointment is an FDA-approved sterile enzymatic debriding ointment which contains 250 collagenase units per gram of white petrolatum USP. The enzyme SANTYL® is derived from the fermentation by Clostridium histolyticum. It possesses the unique ability to digest collagen in necrotic tissue. SANTYL® Ointment is indicated for debriding chronic dermal ulcers and severely burned areas.
Study NCT00543166 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dehydroepiandrosterone
Description: 50 mg of dehydroepiandrosterone in the morning for 4 months in the treatment group.
Study NCT01870414 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: cryotherapy by immersion
Description: the dominant leg was immersed in cold water for 20 minutes \[2, 17\], temperature of 4º C \[22, 24\], water level at 20 cm
Study NCT02324088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study NCT02324088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Study NCT02324088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT02324088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Study NCT02324088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Study NCT02683356 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OCT-guided PCI
Description: Patients assigned to the OCT-guided PCI strategy will undergo OCT prior to PCI to determine vessel and lesion dimensions and treatment strategy. OCT will be repeated at the end of the procedure and corrective PCI will aim to optimize the PCI result according to pre-specified criteria in terms of minimal lumen area, scaffold expansion, apposition, residual dissections or intra-scaffold thrombus formation
Study NCT02683356 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Angiography-guided PCI
Description: Patients assigned to the OCT-guided PCI strategy will only undergo OCT after PCI to determine vessel and lesion dimensions and treatment strategy.
Study NCT03306693 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional skills
Description: 2-hour 3 group sessions
Study NCT03306693 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Relaxation and talking group
Description: 2-hour 3 group sessions
Study NCT02840071 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological therapy
Description: Acceptance and commitment therapy is a third-wave cognitive behavioural therapy. The aim of ACT intervention is to increase a person's psychological flexibility by enabling them to change their relationship with distressing cognitions (acceptance) and doing things that are personally meaningful to them (commitment). The ACT model does not focus on distress reduction, although this is a secondary consequence of acceptance and commitment. This is targeted through the six core processes: present moment awareness, cognitive defusion, acceptance, self-as-context, values and committed action which means taking effective action, guided by the identified values. The intervention will involve six 1.5 hourly individual sessions.
Study NCT01924806 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WoundWand™ Debridement Device
Description: Group I - Electrical energy that removes necrotic, ischemic, and/or infected tissue within a wound
Study NCT01924806 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care sharp debridement
Description: Group II - Sharp instruments that remove necrotic, ischemic, and/or infected tissue within a wound
Study NCT03951935 — intervention group
Intervention type: OTHER
Intervention: Oswestry Disability Index (ODI) questionnaire
Description: Participant's level of low back pain and the extent to which the pain impacts his/ her daily life activities and social life are estimated with the standardized Oswestry Disability Index questionnaire
Study NCT04456868 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: walking test
Description: 8-Meter walking test will be done for gait parameter assessment
Study NCT03951935 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: self-paced walking test (SPWT)
Description: walking back and forth at a self-selected pace along a hallway at the University Hospital until the onset of claudication, pain or until reaching the time limit of 30 minutes. Kinematic and electromyographic (EMG) data will be recorded every 3 minutes.
Study NCT01026714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flurbiprofen
Description: assessment of flurbiprofen plasmatic and capillary rates
Study NCT01026714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flurbiprofen, rifampicin
Description: assessment of flurbiprofen plasmatic and capillary rates
Study NCT01026714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flurbiprofen + fluconazole
Description: assessment of flurbiprofen plasmatic and capillary rates
Study NCT02327273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-963272
Study NCT02327273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT04456868 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: walking test
Description: 8-Meter walking test will be done for gait parameter assessment
Study NCT04456868 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality of life questionnaire
Description: Starkstein Apathy Scale, DSM-5 criteria, Montgomery-Åsberg Depression Rating Scale, Perseverative Thinking Questionnaire, classification of Hoehn \& Yahr
Study NCT04456868 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Quality of life questionnaire
Description: Starkstein Apathy Scale, DSM-5 criteria, Montgomery-Åsberg Depression Rating Scale, Perseverative Thinking Questionnaire, classification of Hoehn \& Yahr
Study NCT04456868 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Position emission tomography
Description: Position emission tomography will be done for
Study NCT04456868 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Position emission tomography
Description: Position emission tomography will be done for
Study NCT00887523 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: radiation in prone position
Description: radiation in prone position
Study NCT00887523 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: radiation in supine position
Description: radiation in supine position
Study NCT04010526 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: local co-administration of autologous ADIpose
Description: local co-administration of autologous ADIpose derived stromal vascular fraction and microfat for refractory perianal CROHN's fistulas Each batch of the final product is composed of one 5 mL syringes containing 25,9 +/- 10,7 millions viable cells. Each syringe will be obstructed with a sterile stopper and packaged in an external packaging.
Study NCT04010526 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: local co-administration of placebo The study placebo will consist of a saline solution for intralesional administration and will follow the same administration schema described for the SFV
Study NCT02076503 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET-MR 18f-FACBC
Study NCT02076503 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: histology (gold standard)
Description: histopathological classification of co-located dissected lymph nodes
Study NCT02210247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EXPAREL
Study NCT00006398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol Maleate
Study NCT00006398 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04433715 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ICIQ-SF
Description: All participants completed ICIQ-SF,
Study NCT03291899 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Description: combination chemotherapy using Oxaliplatin, Irinotecan, Leucovorin and Fluorouracil, given every 15 days for a total of 12 cycles
Study NCT02937051 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco product administration and assessment
Description: two bouts of 10 puffs of a tobacco product with a 30-second interpuff interval separated by 60 minutes; preceded and followed by physiological, subjective and topography assessment
Study NCT02937051 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco product administration and assessment
Description: two bouts of 10 puffs of a tobacco product with a 30-second interpuff interval separated by 60 minutes; preceded and followed by physiological, subjective and topography assessment
Study NCT00658983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous Platelet Enriched Gel
Description: Treatment with Autologous Platelet Enriched Gel
Study NCT00658983 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Metalloproteinase Inhibitor
Description: Treatment with Metalloproteinase Inhibitor (Promogran)
Study NCT04433715 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: UDI-6
Description: All participants completed UDI-6
Study NCT04433715 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: IIQ-7
Description: All participants completed IIQ-7
Study NCT03986983 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shockwave therapy
Description: Shockwave therapy protocol - The shockwave therapy protocol was performed in the prone position. The application was radial shockwave with 3,5bar, 15Hz of frequency and 3000 impulses.
Study NCT03986983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Aerobic exercise protocol - 30 minutes of aerobic moderate-intensity exercise (40% of reserve heart rate) using Karvonen´s formula, performed on a step.
Study NCT04091919 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 2D- Transthoracic Echocardiography (TTE)
Description: 2D- Transthoracic Echocardiography (TTE) derived Tissue Doppler and Strain imaging
Study NCT01602003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LC15-0444 25mg bid
Description: Each patient was given 3 different bottles of study drugs that comprised of two morning bottles and one evening bottles. Each morning bottle contained LC15-0444 25 mg or 50 mg or Sitagliptin 100mg(depending on the randomized group) or its matching placebo while the evening bottle contained LC15-0444 25 mg or its matching placebo. Patient was instructed to take 1 tablet from each bottle at regular times in the morning and evening every day during the 24-week double-blind treatment period.
Study NCT01602003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LC15-0444 50mg qd
Description: Each patient was given 3 different bottles of study drugs that comprised of two morning bottles and one evening bottles. Each morning bottle contained LC15-0444 25 mg or 50 mg or Sitagliptin 100mg(depending on the randomized group) or its matching placebo while the evening bottle contained LC15-0444 25 mg or its matching placebo. Patient was instructed to take 1 tablet from each bottle at regular times in the morning and evening every day during the 24-week double-blind treatment period.
Study NCT01602003 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin 100mg qd
Description: Each patient was given 3 different bottles of study drugs that comprised of two morning bottles and one evening bottles. Each morning bottle contained LC15-0444 25 mg or 50 mg or Sitagliptin 100mg(depending on the randomized group) or its matching placebo while the evening bottle contained LC15-0444 25 mg or its matching placebo. Patient was instructed to take 1 tablet from each bottle at regular times in the morning and evening every day during the 24-week double-blind treatment period.
Study NCT02788617 — intervention group
Intervention type: DEVICE
Intervention: Diafert
Description: The Diafert output, the G-CSF concentration in FF, will be recorded but will not be used in patient management.
Study NCT01213615 — intervention group
Intervention type: DEVICE
Intervention: Valve replacement
Description: Aortic valve replacement of Hancock II Ultra porcine bioprosthesis
Study NCT03334773 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition education
Study NCT02384083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filanesib, pomalidomide and dexamethasone
Description: Patients will be treated with 28-day cycles of Filanesib administered iv as a 1-hour (± 10-minute) infusion at escalating doses on days 1, 2, 15 \& 16, + pomalidomide administered p.o. at escalating doses during 21 days with 7 days rest period + dexamethasone at a fixed dose of 40 mg po days 1, 8, 15 \& 22. G-CSF prophylaxis is mandatory in all patients after Filanesib, starting from Day 3 and Day 17 (for a total of 7 days each). Treatment will be continued until progression or unacceptable toxicity.
Study NCT01580007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Sodium Phenylbutyrate and active cholecalciferol
Description: Sodium Phenylbutyrate: 500 mg twice daily orally for 2 months Cholecalciferol: 5000 IU once daily orally for 2 months
Study NCT01580007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Sodium Phenylbutyrate plus active cholecalciferol
Description: Placebo Sodium Phenylbutyrate: twice daily orally for 2 months Cholecalciferol: 5000 IU once daily for 2 months
Study NCT01580007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Sodium Phenylbutyrate and placebo cholecalciferol
Description: Sodium phenylbutyrate: 500 mg twice daily orally for 2 months Placebo cholecalciferol: once daily orally for 2 months
Study NCT01580007 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Sodium Phenylbutyrate plus placebo cholecalciferol
Description: Placebo Sodium Phenylbutyrate: twice daily orally for 2 months Placebo cholecalciferol: once daily orally for 2 months
Study NCT00525811 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: patient dialogue
Description: Information on shared decision making, how to participate in medical decision making, information on acute low back pain, information on depression
Study NCT00525811 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: patient information
Description: Information on acute low back pain, information on depression
Study NCT01904292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Subcutaneous 162 mg dose QW or Q2W for 52 weeks
Study NCT03580408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240 mg
Study NCT03580408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastin
Description: 6mg/m²
Study NCT00593710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Losartan (25mg OD)
Study NCT00593710 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol
Description: Atenolol (25-50mg OD)
Study NCT00419653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amisulpride
Study NCT00419653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Study NCT05562583 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SAGE LEAF
Description: SAGE LEAF covers 8 skills and each skill has related home-practice activities that unlock every week. Each week will consist of 1-2 days of didactic material and 5-6 days of real-life home practice. Participants can access the skills at their own leisure and as often as they'd like within that week. Participants cannot skip modules with didactic material and can only progress to the next lesson if they have completed the current one. However, participants can return to old lessons or exercises if they choose to do so at a later time.
Study NCT01748422 — intervention group
Intervention type: DRUG
Intervention: Qutenza
Description: Transdermal patch
Study NCT04979195 — intervention group
Intervention type: OTHER
Intervention: Patients with stable normal kidney function
Description: Covid-19 patients with stable kidney function will represent group 1.
Study NCT04979195 — intervention group
Intervention type: OTHER
Intervention: Patients with unstable kidney function
Description: Covid-19 patients with unstable kidney function will represent group 2.
Study NCT04569422 — intervention group
Intervention type: DRUG
Intervention: Benoxyl
Description: reduce pain
Study NCT03942068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin-bound paclitaxel
Description: Nanoparticle albumin-bound paclitaxel (nab-paclitaxel), a microtubule inhibitor
Study NCT03942068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: a novel oral antiangiogenic agent targeting vascular endothelial growth factor receptor (VEGFR2)
Study NCT03928756 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Push Notifications with Tailored Intervention Content
Description: Participants will receive a push notification with a therapeutic message (e.g., about stress, mood, substance use motives, tools to reduce risky substance use) tailored to their recent daily or weekly survey responses. Messages include visual (memes, images, videos) and written content.
Study NCT03928756 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Push Notifications with Engaging, Non-therapeutic Content
Description: Participants will receive a push notification with an engaging, non-therapeutic message (e.g., fun facts).
Study NCT03928756 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Push Notifications
Description: Participants will not receive a push notification.